Search
for
Sort by
Research 481–510 of 1000+
- Effective treatment of folliculitis decalvans using selected antimicrobial agents
- What does acne genetics teach us about disease pathogenesis?
- Dermatologic therapy: December 1986 to December 1987
- Keratin disorders: from gene to therapy
- Geriatric Dermatologic Therapy
- Prolactin as a candidate sebotrop(h)ic hormone?
- Immune cell regulation of the hair cycle
- Isotretinoin for the treatment of facial lichen planopilaris: A new indication for an old drug, a case series study
- Conference 2022, The Sequel
- "Psycho-affective Implications in Dermatoaesthetics "
- Subject Index
- BOOK REVIEWS
- The spectrum of nephrocutaneous diseases and associations
- Dermatological considerations for transgender and gender diverse patients: An Australian perspective
- The Effectiveness of Topical Keratolytics (Alpha Hydroxy Acids/Beta Hydroxy Acids/Urea) in Treating Keratosis Pilaris: A Review of the Literature
- Methotrexate in dermatology
- Botanicals With Dermatologic Properties Derived From First Nations Healing: Part 1—Trees
- Annual Convention in the Time of COVID
- Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report
- Severe pityriasis rubra pilaris complicated with Kaposi's varicelliform eruption and cutaneous MRSA infection case report
- Exploring the Interplay between Arsenic and Cutaneous Physiology, Pathology, and Regeneration
- Acquired scalp alopecia. Part I: A review
- Advances in Hair Diseases
- Therapeutic Application of Microsponges-based Drug Delivery Systems
- Maternal Faecalibacterium pathobionts and low-fiber diets synergize to impact offspring health: implications for atopic dermatitis
- Effects of a cyclosporine-based protocol in canine granulomatous sebaceous adenitis - case series
- Finasteride in androgenetic alopecia in men
- Hydrogen peroxide and monoethanolamine are the key causative ingredients for hair dye-induced dermatitis and hair loss
- Lichen Planopilaris: Update on Diagnosis and Treatment
- Management of Toxicities of Targeted Therapies